



Universiteit  
Leiden  
The Netherlands

## Innovation in cholinergic enhancement for Alzheimer's Disease

Baakman, A.C.

### Citation

Baakman, A. C. (2021, November 17). *Innovation in cholinergic enhancement for Alzheimer's Disease*. Retrieved from <https://hdl.handle.net/1887/3240157>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded  
from: <https://hdl.handle.net/1887/3240157>

**Note:** To cite this publication please use the final published version (if applicable).

INNOVATION IN CHOLINERGIC ENHANCEMENT FOR ALZHEIMER'S DISEASE





# **Innovation in cholinergic enhancement in Alzheimer's Disease**

PROEFSCHRIFT  
ter verkrijging van  
de graad van doctor aan de Universiteit Leiden,  
op gezag van rector magnificus prof.dr.ir. H. Bijl,  
volgens besluit van het college voor promoties  
te verdedigen op woensdag 17 november 2021  
klokke 11.15 uur

DOOR  
Annechiena Catharina Baakman  
geboren te Vollenhove in 1983

**PROMOTORES**

Prof. dr. J.M.A. van Gerven

Prof. dr. P. Scheltens

Prof. dr. G.J. Groeneveld

**LEDEN PROMOTIECOMMISSIE**

Prof. dr. O.C. Meijer

Prof. dr. W.M. van der Flier (Amsterdam UMC)

Prof. dr. G.J. Blauw

Dr. A.W. Lemstra (Amsterdam UMC)

**7 Introduction****21 Chapter 2**

No synergistic effect of subtherapeutic doses of donepezil and EVP-6124 in healthy elderly subjects in a scopolamine challenge model.

**37 Chapter 3**

An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine.

**57 Chapter 4**

Pharmacokinetics and pharmacodynamics of oral mecamylamine - development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation.

**81 Chapter 5**

First in human study with a prodrug of galantamine: Improved benefit-risk ratio?

**97 Chapter 6**

Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's Disease.

**121 Chapter 7**

Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers.

**147 Chapter 8**

Discussion

**157 Dutch summary****165 Curriculum Vitae****167 List of publications****COVER**

Geertje Piësla-Roodbol, Amsterdam

**DESIGN**

Caroline de Lint, Voorburg (caro@delint.nl)

*All rights reserved. No part from this thesis may be reproduced, distributed or transmitted in any form or by any means, without prior written permission of the author.*

*Publication of this thesis was financially supported by the foundation Centre for Human Drug Research, Leiden, the Netherlands.*